Serum lipidomics reveals early differential effects of gastric bypass compared with banding on phospholipids and sphingolipids independent of differences in weight loss

International Journal of Obesity

Volumn 41, Issue 6, 2017, Pages 917-925

  Kayser, B D ^a,b,c   Lhomme, M ^a   Dao, M C ^a,b,c   Ichou, F ^a   Bouillot, J L ^d   Prifti, E ^a   Kontush, A ^a,b,c   Chevallier, J M ^e   Aron Wisnewsky, J ^a,b,c   Dugail, I ^a,b,c   Clement K ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Institute OfCardiometabolism and Nutrition   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARBON FATTY ACID; CERAMIDE; FATTY ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; OROSOMUCOID; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOMYELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CHOLESTEROL;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FALSE DISCOVERY RATE; FEMALE; FOLLOW UP; GASTRIC BANDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN SENSITIVITY; LABORATORY TEST; LIMIT OF QUANTITATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPIDOMICS; MAJOR CLINICAL STUDY; MCAULEY INDEX; METABOLIC PARAMETERS; OBESITY; PHOSPHOLIPID METABOLISM; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; ROUX-EN-Y GASTRIC BYPASS; SPHINGOLIPID METABOLISM; TANDEM MASS SPECTROMETRY; WEIGHT REDUCTION; X RAY BONE DENSITOMETER; BLOOD; BODY WEIGHT LOSS; COMPARATIVE STUDY; DIET RESTRICTION; FRANCE; GASTRIC BYPASS SURGERY; GASTROPLASTY; LIPID METABOLISM; MORBID OBESITY; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BIOMARKERS; CERAMIDES; CHOLESTEROL; FASTING; FEMALE; FOLLOW-UP STUDIES; FRANCE; GASTRIC BYPASS; GASTROPLASTY; HUMANS; LIPID METABOLISM; OBESITY, MORBID; PHOSPHOLIPIDS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; SPHINGOLIPIDS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85017030652     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2017.63     Document Type: Article

References (49)

1. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
2. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012; 143: 897-912.
3. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: A 5-year controlled longitudinal study. Ann Surg 2014; 260: 893-898.
4. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.
5. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: e5.
6. Heffron SP, Parikh A, Volodarskiy A, Ren-Fielding C, Schwartzbard A, Nicholson J et al. Changes in lipid profile of obese patients following contemporary bariatric surgery: A meta-analysis. Am J Med 2016; 129: 952-959.
7. Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab 2015; 21: 369-378.
8. Bradley D, Conte C, Mittendorfer B, Eagon JC, Varela JE, Fabbrini E et al. Gastric bypass and banding equally improve insulin sensitivity and cell function. J Clin Invest 2012; 122: 4667-4674.
9. Jackness C, Karmally W, Febres G, Conwell IM, Ahmed L, Bessler M et al. Very lowcalorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and-cell Function in type 2 diabetic patients. Diabetes 2013; 62: 3027-3032.
10. Sjöholm K, Sjöström E, Carlsson LMS, Peltonen M. Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: Two-and 10-year results from the Swedish Obese Subjects (SOS) Study. Diabetes Care 2016; 39: 625-631.
11. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010; 51: 3299-3305.
12. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med 2011; 365: 1812-1823.
13. Anjani K, Lhomme M, Sokolovska N, Poitu C, Aron-Winewsky J, Bouillot B et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatology 2015; 62: 905-912.
14. Gorden DL, Myers DS, Ivanova PT, Fahy E, Maurya MR, Gupta S et al. Biomarkers of NAFLD progression: A lipidomics approach to an epidemic. J Lipid Res 2015; 56: 722-736.
15. van der Veen JN, Lingrell S, Vance DE. The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver. J Biol Chem 2012; 287: 23418-23426.
16. Camont L, Lhomme M, Rached F, Le Goff W, Nègre-Salvayre A, Salvayre R et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013; 33: 2715-2723.
17. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011; 121: 4222-4230.
18. Boon J, Hoy AJ, Stark R, Brown RD, Meex RC, Henstridge DC et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 2013; 62: 401-410.
19. Ciangura C, Bouillot JL, Lloret-Linares C, Poitou C, Veyrie N, Basdevant A et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity (Silver Spring) 2010; 18: 760-765.
20. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464.
21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
22. Palarea-Albaladejo J, Martin-Fernandez JA. Values below detection limit in compositional chemical data. Anal Chim Acta 2013; 764: 32-43.
23. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011; 6: 1060-1083.
24. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007; 3: 211-221.
25. Little RA, Rubin DB. Statistical Analysis With Missing Data. John Wiley & Sons: Hoboken, NJ, USA, 2002.
26. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipid profiling of FPLCseparated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009; 50: 574-585.
27. Meikle PJ, Wong G, Barlow CK, Weir JM, Greeve MA, MacIntosh GL et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 2013; 8: e74341.
28. Graessler J, Bornstein TD, Goel D, Bhalla VP, Lohmann T, Wolf T et al. Lipidomic profiling before and after Roux-en-Y gastric bypass in obese patients with diabetes. Pharmacogenomics J 2014; 14: 201-207.
29. Huang H, Kasumov T, Gatmaitan P, Heneghan HM, Kashyap SR, Schauer PR et al. Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity 2011; 19: 2235-2240.
30. Arora T, Velagapudi V, Pournaras DJ, Welbourn R, le Roux CW, Oreši M et al. Rouxen-Y gastric bypass surgery induces early plasma metabolomic and lipidomic alterations in humans associated with diabetes remission. PLoS One 2015; 10: e0126401.
31. Mutch DM, Fuhrmann JC, Rein D, Wiemer JC, Bouillot JL, Poitou C et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One 2009; 4: e7905.
32. Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 2002; 277: 42358-42365.
33. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006; 3: 5.
34. Sigruener A, Kleber ME, Heimerl S, Liebisch G, Schmitz G, Maerz W. Glycerophospholipid and sphingolipid species and mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS One 2014; 9: e85724.
35. Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol 2016; 13: 79-91.
36. Levy M, Futerman AH. Mammalian ceramide synthases. IUBMB Life 2010; 62: 347-356.
37. Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014; 20: 687-695.
38. Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014; 20: 678-686.
39. Gosejacob D, Jäger PS, Vom Dorp K, Frejno M, Carstensen AC, Köhnke M et al. Ceramide synthase 5 is essential to maintain C16:0 ceramide pools and contributes to the development of diet induced obesity. J Biol Chem 2016; 291: 6989-7003.
40. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH et al. Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans. Diabetologia 2016; 59: 785-798.
41. Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J 2016; 37: 1967-1976.
42. Merrill AH, Lingrell S, Wang E, Nikolova-Karakashian M, Vales TR, Vance DE. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J Biol Chem 1995; 270: 13834-13841.
43. Watt MJ, Barnett AC, Bruce CR, Schenk S, Horowitz JF, Hoy AJ. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 2012; 55: 2741-2746.
44. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH et al. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab 2015; 309: E398-E408.
45. Chaston TB, Dixon JB, O'Brien PE. Changes in fat-free mass during significant weight loss: A systematic review. Int J Obes (Lond) 2007; 31: 743-750.
46. Memon RA, Holleran WM, Moser AH, Seki T, Uchida Y, Fuller J et al. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc Biol 1998; 18: 1257-1265.
47. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003; 419: 101-109.
48. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125: 386-402.
49. Aron-Wisnewsky J, Verger EO, Bounaix C, Dao MC, Oppert JM, Bouillot JL et al. Nutritional and protein deficiencies in the short term following both gastric bypass and gastric banding. PLoS One 2016; 11: e0149588.